title: Brain nuclear factor kappa B is involved in the corticotropin-releasing factor-induced central activation of sympatho-adrenomedullary outflow in rats.
abstract: Using urethane-anesthetized rats, we examined whether an activation of nuclear factor kappa B is involved in the corticotropin-releasing factor-induced increase in plasma levels of catecholamines. An intracerebroventricularly administered corticotropin-releasing factor (1.5 nmol/animal)-induced increase of plasma catecholamines was dose-dependently reduced by pyrrolidine dithiocarbamate (a nuclear factor kappa B antagonist) (1 and 9 nmol/animal, intracerebroventricularly) and SN50 (a peptide inhibiting nuclear factor kappa B translocation) (9 and 18 nmol/animal, intracerebroventricularly), while SN50M (an inactive control peptide for SN50, 19 nmol/animal, intracerebroventricularly) had no effect on the corticotropin-releasing factor-induced elevation of both catecholamines. Furthermore, the corticotropin-releasing factor-induced responses were also attenuated by rosiglitazone (a peroxisome proliferator-activated receptor-gamma agonist)(50 nmol/animal, intracerebroventricularly). These results suggest the involvement of brain nuclear factor kappa B in the corticotropin-releasing factor-induced central activation of the sympatho-adrenomedullary outflow in rats.
authors.affiliation: Department of Pharmacology, Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan. okadas@kochi-u.ac.jp
authors.forename: Shoshiro
authors.initials: S
authors.lastname: Okada
authors.forename: Naoko
authors.initials: N
authors.lastname: Yamaguchi-Shima
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shimizu
authors.forename: Junichi
authors.initials: J
authors.lastname: Arai
authors.forename: Mieko
authors.initials: M
authors.lastname: Yorimitsu
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Yokotani
mesh_terms: D000313:Adrenal Medulla / Q000294:innervation* / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood; D007276:Injections, Intraventricular; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009434:Neural Pathways / Q000378:metabolism; D009638:Norepinephrine / Q000097:blood; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000378:metabolism*; D045162:Thiazolidinediones / Q000494:pharmacology; D013859:Thiocarbamates / Q000494:pharmacology; D013997:Time Factors; D015854:Up-Regulation
chemical_list: D016328:NF-kappa B; D047495:PPAR gamma; D010455:Peptides; D011759:Pyrrolidines; C118258:SN50 peptide; D045162:Thiazolidinediones; D013859:Thiocarbamates; D000077154:Rosiglitazone; C020972:pyrrolidine dithiocarbamic acid; D003346:Corticotropin-Releasing Hormone; D009638:Norepinephrine; D004837:Epinephrine